U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Main content area

Vaccination with a porcine reproductive and respiratory syndrome (PRRS) modified live virus vaccine followed by challenge with PRRS virus and porcine circovirus type 2 (PCV2) protects against PRRS but enhances PCV2 replication and pathogenesis compared to Results for Nonvaccinated Cochallenged Controls

Megan C. Niederwerder, Bhupinder Bawa, Nick V. L. Serão, Benjamin R. Trible, Maureen A. Kerrigan, Joan K. Lunney, Jack C. M. Dekkers, Raymond R. R. Rowland
Clinical and Vaccine Immunology 2015 v.22 no.12 pp. 1244-1254
Porcine circovirus-2, Porcine reproductive and respiratory syndrome virus, average daily gain, disease models, immunity, mixed infection, mortality, pathogenesis, porcine reproductive and respiratory syndrome, protective effect, signs and symptoms (animals and humans), swine, vaccination, vaccines, viremia, virus replication, viruses
Coinfections involving porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus type 2 (PCV2) contribute to a group of disease syndromes known as porcine circovirus-associated disease (PCVAD). Presumably, PRRSV infection enhances PCV2 replication as a result of modulation of host immunity. The purpose of this study was to evaluate PCV2 replication and pathogenesis in pigs vaccinated with a PRRS modified live virus (MLV) vaccine and subsequently challenged with a combination of PRRSV and PCV2. During the early postchallenge period, the number of pigs with PRRSV-associated clinical signs was decreased, and average daily gain (ADG) was increased, in the vaccinated group, demonstrating the protective effect of PRRS vaccination. However, during the later postchallenge period, more pigs in the vaccinated group showed increased PCV2 viremia, decreased ADG, increased PCVAD clinical signs, and increased mortality. In this disease model, the early benefits of PRRSV vaccination were outweighed by the later amplification of PCVAD.